Detailed Narrative
Go-to-Market Strategy Evolution
Myomo is successfully transitioning its go-to-market strategy from direct-to-consumer marketing to a more durable model emphasizing recurrent patient referrals. This shift has led to recurring patient sources accounting for 53% of total revenue, a significant increase from 26% a year ago, and achieving the 50% objective six months ahead of schedule. The MyoConnect program, which facilitates direct billing referrals, is a key driver, contributing 23% of total revenue and showing higher conversion rates for medically qualified patients with better insurance coverage.
Operational Efficiency and Cost Reduction
The company demonstrated strong operating leverage, with revenue growing 21% while operating expenses increased by less than 1%. This led to a substantial improvement in adjusted EBITDA, reducing the loss to $800,000 from $4 million in the prior year. Initiatives include a Six Sigma team executing cost reduction, a mobile app rollout to replace laptops, expanding in-house assembly, and investing in 3D printing capabilities, all aimed at expanding margins and lowering cash burn.
Product Development and Market Expansion
Myomo continues to innovate on its wearable robotics platform, with the next-generation MyoPro 3 development on schedule. A hand-only prototype was introduced at the OTWorld Conference in Germany, targeting the German market first due to existing reimbursement for such devices. This expansion into hand-only functionality broadens the addressable market and leverages the existing technology platform, with plans to explore U.S. rollout after securing appropriate reimbursement codes.
Payer Access and Clinical Evidence
Market access is expanding through new agreements, including additional Elevance state contracts and in-network status with Optum's workers' compensation product (UnitedHealthcare). These agreements are leading to higher authorization rates. The University of Utah randomized controlled trial (RCT) is progressing, with 25 of 50 patients enrolled, and a 6-month outcomes publication expected in the second half of the year, which is anticipated to further support reimbursement and demand generation.
Board Enhancement and Investor Engagement
Myomo enhanced its Board of Directors with the appointment of Joe Manko and Will Febbo, adding significant industry experience, financial expertise, and leadership in building shareholder value. The company also plans to participate in the H.C. Wainwright 28th Annual Global Investment Conference in September to engage with investors.